Comorbidities significantly impact patients’ preferences for psoriasis treatments - 11/08/12
, Marthe-Lisa Schaarschmidt a, Nasir Umar, MSc b, Darcy D. Terris, PhD b, c, Matthias Goebeler, MD a, d, Sergij Goerdt, MD a, Wiebke K. Peitsch, MD a, ⁎ 
Reprint requests: Astrid Schmieder, MD, Department of Dermatology, University Medical Centre Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68135 Mannheim, Germany.Correspondence to: Wiebke K. Peitsch, MD, Department of Dermatology, University Medical Centre Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68135 Mannheim, Germany.Abstract |
Background |
Non-adherence rates are high among patients with psoriasis, partly because of discordance between recommended treatments and individual preferences.
Objectives |
Our aim was to assess the impact of comorbidities on patients’ preferences for psoriasis treatments.
Methods |
A computer-based conjoint analysis experiment was conducted to analyze preferences of patients with psoriasis (N = 163) for treatment outcome attributes (probability, magnitude and duration of benefit; probability, severity and reversibility of side effects) and process attributes (treatment location, frequency, duration, delivery method, individual cost). The impact of comorbidities (psoriatic arthritis, cardiovascular disease, diabetes, and depression) on relative importance scores of each attribute was assessed by analyses of variance, post hoc test, and multivariate regression analysis.
Results |
Among the participants included (58.9% males, mean age 49.3 yrs), 27% suffered from psoriatic arthritis, 13.5% from cardiovascular disease, 8% from diabetes, and 12.9% from depression. Preferences for treatment attributes varied significantly depending on comorbidities. Participants with psoriatic arthritis cared most about the probability of benefit (β 0.166; P = .037), whereas those participants with cardiovascular disease were highly concerned about the probability of side effects (β 0.179; P = .046). For participants with depression, treatment duration (β 0.163; P = .047), and individual cost (P = .023) were highly important.
Limitations |
Only patients with moderate and severe psoriasis treated at a university medical center were included.
Conclusions |
Integrating patients’ preferences into shared decision-making may facilitate treatment adherence and optimize outcomes. Addressing patients’ comorbidities, particularly depression, may be a currently neglected opportunity to improve care.
Il testo completo di questo articolo è disponibile in PDF.Key words : adherence, cardiovascular disease, conjoint analysis, depression, diabetes, preferences, psoriasis, psoriatic arthritis
Abbreviations used : ANOVA, CA, CASPAR, DLQI, PUVA, PASI, RIS, SD
Mappa
| Funding sources: None. |
|
| Conflicts of interest: None declared. |
Vol 67 - N° 3
P. 363-372 - settembre 2012 Ritorno al numero
Articolo precedente
- Are patients with psoriasis being screened for cardiovascular risk factors? A study of screening practices and awareness among primary care physicians and cardiologists
- Kory K. Parsi, Elizabeth A. Brezinski, Tzu-Chun Lin, Chin-Shang Li, April W. Armstrong
- Recommendations and current practices for the reconstitution and storage of botulinum toxin type A
- Austin Liu, Alastair Carruthers, Joel L. Cohen, William P. Coleman, Jeffrey S. Dover, C. William Hanke, Ronald L. Moy, David M. Ozog
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?